Plasma Fractionation and Blood Product Market Size, Share, Growth, and Industry Analysis, By Type (Coagulation Factor,Immune Globulin,Albumin,Other), By Application (Immunology,Hematology,Other), Regional Insights and Forecast to 2035

Plasma Fractionation and Blood Product Market Overview

Global Plasma Fractionation and Blood Product market size is estimated at USD 5230.24 million in 2026 and expected to rise to USD 6687.69 million by 2035, experiencing a CAGR of 2.8%.

The Plasma Fractionation and Blood Product Market represents a critical segment of the global biopharmaceutical industry, with more than 60 million liters of plasma collected globally in 2023 for fractionation purposes. Over 80% of plasma-derived medicinal products (PDMPs) are utilized in treating rare and chronic conditions such as primary immunodeficiency disorders, hemophilia, and autoimmune diseases. Approximately 70% of collected plasma worldwide is processed into immune globulin, while albumin accounts for nearly 20% and coagulation factors represent around 8%. The Plasma Fractionation and Blood Product Market Size is strongly influenced by rising demand from over 6 million patients globally requiring immunoglobulin therapy annually.

In the United States, the Plasma Fractionation and Blood Product Market accounts for nearly 65% of global plasma collection volume, with more than 900 licensed plasma collection centers operational across 40 states in 2024. The U.S. supplies approximately 70% of the world’s source plasma for fractionation. More than 125,000 plasma donations occur daily across the country, contributing to over 50 million liters annually. The Plasma Fractionation and Blood Product Market Analysis in the U.S. highlights that immune globulin utilization exceeds 55% of total plasma-derived product consumption, with over 150,000 patients receiving regular immunoglobulin infusions monthly.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 65% demand growth stems from immunoglobulin therapy, with 40% autoimmune, 30% primary immunodeficiency, and 25% neurological indications.
• Major Market Restraint: Around 45% supply risk from donor dependency, 35% regulatory delays, 28% attrition rates, and 20% manufacturing bottlenecks globally.
• Emerging Trends: Over 50% manufacturers expand capacity, 38% adopt SCIG, 42% automate processing, and 33% integrate digital donor systems.
• Regional Leadership: North America leads with 55%, Europe 25%, Asia-Pacific 15%, and Middle East & Africa contribute 5% share.
• Competitive Landscape: Top 5 companies control 75% capacity, top 2 hold 40%, while 60% smaller players remain regionally focused.
• Market Segmentation: Immune globulin 55%, albumin 20%, coagulation factors 8%, others 17%, immunology applications 60%, hematology 25% demand.
• Recent Development: From 2023–2025, 30% expansions announced, 20% new centers added, 15% SCIG launches, 10% hybrid therapies growth.

Plasma Fractionation and Blood Product Market Latest Trends

The Plasma Fractionation and Blood Product Market Trends indicate that immunoglobulin demand accounts for over 55% of plasma protein usage globally in 2024. Subcutaneous immunoglobulin (SCIG) represents nearly 38% of total immunoglobulin administration compared to 62% intravenous routes. More than 45 new plasma collection centers were opened globally between 2023 and 2024, increasing collection capacity by approximately 8%. Automation integration in fractionation plants has increased by 42%, reducing processing time by nearly 15%.

Albumin demand represents 20% of total plasma-derived products, with Asia accounting for nearly 50% of global albumin consumption due to surgical and liver disease applications. Coagulation factors represent around 8% of product share, with hemophilia A affecting nearly 1 in 5,000 male births worldwide. More than 75% of fractionation facilities operate with cold ethanol fractionation technology, while 25% utilize chromatographic purification techniques. Plasma Fractionation and Blood Product Market Insights indicate that over 70% of companies are investing in pathogen inactivation technologies to enhance product safety.

Plasma Fractionation and Blood Product Market Dynamics

DRIVER

"Rising demand for immunoglobulin therapies"

The Plasma Fractionation and Blood Product Market Growth is strongly driven by immunoglobulin demand, which represents nearly 55% of total plasma-derived product consumption worldwide. More than 6 million patients receive IVIG or SCIG therapy annually, with autoimmune neurological disorders accounting for approximately 35% of prescriptions. Primary immunodeficiency affects nearly 1 in 1,200 individuals globally, and diagnosis rates have increased by 20% over the past 10 years due to improved screening. The global population aged 65 years and above is projected to reach 16% in 2025, significantly increasing chronic disease prevalence. Immunoglobulin dosage requirements often exceed 400 grams per patient annually, intensifying plasma utilization rates.

RESTRAINT

"Dependence on plasma donor availability"

The Plasma Fractionation and Blood Product Market faces structural constraints due to heavy reliance on plasma donors, with nearly 65% of global plasma supply originating from the United States. Donor return rates declined by approximately 18% during pandemic-related disruptions, exposing vulnerabilities in collection systems. Plasma donors typically contribute 2 to 3 times per week, limiting rapid scaling of supply beyond existing infrastructure capacity. Regulatory compliance requirements have increased by 25% in the past five years, extending product approval timelines by nearly 12%. Around 30% of countries depend significantly on imported plasma-derived products, resulting in supply imbalances and reduced national self-sufficiency ratios below 50%.

OPPORTUNITY

"Expansion in emerging markets"

Emerging economies present strong Plasma Fractionation and Blood Product Market Opportunities, with Asia-Pacific plasma demand rising by 15% between 2022 and 2024. China accounts for nearly 30% of regional fractionation capacity, supported by more than 300 licensed plasma collection stations. India maintains less than 10% domestic plasma sufficiency, with import dependency exceeding 60%, creating room for infrastructure expansion. Healthcare expenditure on biologics in the Middle East increased by 22% in 2023, supporting immunoglobulin access programs. Globally, hemophilia prevalence is estimated at approximately 400,000 cases, and diagnosis improvements of 10% to 15% annually in developing countries are expanding coagulation factor demand significantly.

CHALLENGE

"High manufacturing complexity and compliance"

Manufacturing complexity remains a major challenge in the Plasma Fractionation and Blood Product Market, as the fractionation process requires more than 9 months from plasma donation to final product release. Each batch undergoes over 20 mandatory quality control tests, increasing operational expenditure by nearly 15%. Fractionation yields for specific proteins range between 3% and 5% per liter of plasma, limiting output efficiency. Cold chain logistics between 2°C and 8°C are required for 100% of immunoglobulin shipments, adding distribution constraints across 80+ importing countries. Nearly 25% of fractionation facilities require periodic infrastructure upgrades to comply with updated good manufacturing practice standards.

Segmentation Analysis

The Plasma Fractionation and Blood Product Market Segmentation is categorized by type and application. By type, immune globulin accounts for 55%, albumin 20%, coagulation factor 8%, and other derivatives 17%. By application, immunology represents 60%, hematology 25%, and other therapeutic uses 15%. More than 70% of immune globulin is used in chronic therapy, while over 80% of coagulation factors target inherited bleeding disorders.

Download FREE Sample to learn more about this report.

By Type

Coagulation Factor: Coagulation factors represent approximately 8% of the total Plasma Fractionation and Blood Product Market Share, driven primarily by inherited bleeding disorders. Hemophilia A occurs in nearly 1 in 5,000 male births, while Hemophilia B affects around 1 in 25,000 male births globally. The total diagnosed hemophilia population exceeds 400,000 individuals worldwide, with nearly 75% requiring lifelong prophylactic treatment. Plasma-derived factor VIII and factor IX products account for about 40% of global factor consumption, while recombinant alternatives cover 60%.

Immune Globulin: Immune globulin dominates the Plasma Fractionation and Blood Product Market with nearly 55% market share, making it the largest product segment. More than 6 million patients worldwide receive intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy annually. Autoimmune disorders contribute approximately 35% of total prescriptions, while primary immunodeficiency diseases account for 30%. Neurological indications represent nearly 15% of demand. In 2024, SCIG administration reached a 38% share of total immunoglobulin use, reflecting increased home-based treatment adoption.

Albumin: Albumin contributes approximately 20% of the Plasma Fractionation and Blood Product Market Size and remains widely used in acute and chronic care settings. Nearly 50% of global albumin consumption occurs in Asia-Pacific, driven by high surgical volumes and liver disease prevalence. Albumin is utilized in around 45% of advanced liver disease treatments, particularly for cirrhosis and ascites management. Approximately 30% of critical care interventions involving shock or trauma include albumin administration. Surgical procedures account for nearly 25% of total albumin demand.

Other: Other plasma-derived products account for roughly 17% of the Plasma Fractionation and Blood Product Market Share, including alpha-1 antitrypsin, fibrinogen concentrates, and hyperimmune globulins. Alpha-1 antitrypsin deficiency affects approximately 1 in 2,500 individuals of European descent, with over 100,000 diagnosed cases worldwide. Fibrinogen deficiency prevalence is estimated at 1 in 1,000,000, requiring targeted replacement therapy. Fibrin sealants represent nearly 10% of surgical hemostatic applications, particularly in cardiovascular and orthopedic procedures.

By Application

Immunology: Immunology represents approximately 60% of total Plasma Fractionation and Blood Product Market demand, making it the largest application segment. Primary immunodeficiency prevalence is estimated at 1 in 1,200 individuals globally, translating to millions of affected patients. Chronic inflammatory demyelinating polyneuropathy affects around 5 in 100,000 people, contributing to sustained IVIG demand. More than 70% of intravenous immunoglobulin usage is directed toward immunological conditions, including autoimmune encephalitis and myasthenia gravis.

Hematology: Hematology accounts for approximately 25% of application share within the Plasma Fractionation and Blood Product Market. Hemophilia affects nearly 400,000 individuals worldwide, with severe cases representing about 50% of diagnoses. Von Willebrand disease has a prevalence of nearly 1% of the global population, though symptomatic cases represent around 0.1%. Approximately 80% of severe hemophilia patients require regular prophylactic infusions multiple times per week. Coagulation factor concentrates maintain clotting activity levels above 1% to reduce spontaneous bleeding risk. Other: Other applications account for nearly 15% of Plasma Fractionation and Blood Product Market demand, covering critical care, infectious diseases, and surgical support. Sepsis management represents approximately 10% of albumin utilization in hospital settings. Severe burn treatment requires albumin replacement in nearly 20% of critical cases involving extensive fluid loss. Hyperimmune globulins are administered in post-exposure prophylaxis, with rabies immunoglobulin usage exceeding 15 million doses annually worldwide. Plasma-derived fibrin sealants are applied in over 5 million surgical procedures each year.

Regional Outlook

The Plasma Fractionation and Blood Product Market demonstrates strong regional concentration, with North America holding 55% share, Europe 25%, Asia-Pacific 15%, and Middle East & Africa 5%. Over 60 million liters of plasma are processed annually worldwide, supported by more than 1,000 collection centers and 50+ fractionation facilities, reflecting structured global supply distribution and demand-driven infrastructure expansion.

Download FREE Sample to learn more about this report.

North America

North America accounts for nearly 55% of the global Plasma Fractionation and Blood Product Market Size, making it the most dominant regional contributor. The United States alone supplies over 90% of the region’s plasma volume, supported by more than 900–1,000 active plasma collection centers operating across 40+ states. Daily plasma donations in the U.S. exceed 120,000, contributing to more than 50 million liters annually for fractionation. Canada represents approximately 5% of North American consumption, with fewer than 50 collection facilities and increasing reliance on imported plasma-derived medicinal products.

Immunoglobulin products represent around 60% of total regional demand, driven by more than 150,000 patients receiving regular IVIG or SCIG therapy. Hemophilia prevalence in North America is estimated at nearly 20,000 diagnosed cases, supporting sustained coagulation factor demand. Over 70% of global clinical trials related to plasma-derived therapies are conducted in North America, with more than 25 ongoing studies in immunology and hematology. Regulatory oversight includes over 20 mandatory quality control steps per batch, reinforcing product safety standards.

Europe

Europe represents approximately 25% of the global Plasma Fractionation and Blood Product Market Share, with Germany, France, Italy, and Spain collectively contributing nearly 60% of regional demand. Across Europe, around 300 plasma collection centers operate under varying national regulatory systems. Self-sufficiency rates differ significantly, ranging from 20% in some Southern European countries to nearly 80% in nations with structured voluntary donation systems.

Immunoglobulin accounts for roughly 50% of total plasma-derived product utilization, while albumin contributes about 25%, particularly in surgical and liver disease management. Europe processes approximately 12–15 million liters of plasma annually, with several countries importing source plasma to meet domestic needs. More than 10 fractionation facilities are located across Western Europe, ensuring regional manufacturing capacity. Hemophilia prevalence in Europe is estimated at over 35,000 patients, supporting sustained coagulation factor utilization. Regulatory harmonization across more than 25 countries ensures batch release testing, with each lot undergoing 15–20 safety assessments before commercialization.

Asia-Pacific

Asia-Pacific holds nearly 15% of the global Plasma Fractionation and Blood Product Market Size, with strong growth in collection and manufacturing infrastructure. China operates more than 300 licensed plasma collection stations and contributes approximately 30% of regional plasma production. Annual plasma collection in China exceeds 10 million liters, supporting domestic fractionation capacity. Japan accounts for nearly 20% of Asia-Pacific consumption, with high per capita immunoglobulin usage exceeding 120 grams per 1,000 inhabitants annually.

Albumin represents approximately 50% of total plasma product utilization in Asia-Pacific, largely due to demand in liver disease, trauma, and surgical procedures. India imports over 60% of its plasma-derived medicinal product requirements, highlighting infrastructure expansion opportunities. The region includes more than 15 fractionation plants, with capacity expansion projects increasing processing volumes by nearly 2 million liters between 2023 and 2025. Immunoglobulin accounts for about 40% of product utilization, while coagulation factors represent 10%, supported by an estimated 80,000 diagnosed bleeding disorder patients.

Middle East & Africa

The Middle East & Africa region contributes approximately 5% to the global Plasma Fractionation and Blood Product Market Share, with limited domestic fractionation capacity. Saudi Arabia and South Africa together account for nearly 40% of regional demand, supported by centralized healthcare procurement systems. Plasma collection infrastructure remains underdeveloped, with fewer than 100 operational plasma centers across the region. Import dependency exceeds 70% in many African nations, creating supply chain vulnerability for essential plasma-derived therapies.

Immunoglobulin utilization represents around 45% of total plasma product consumption, driven by immunodeficiency and autoimmune disorder treatment. Albumin accounts for approximately 30% of usage, particularly in trauma care and critical care settings. The region reports more than 15,000 diagnosed hemophilia patients, sustaining demand for coagulation factors. Regulatory oversight varies across over 20 jurisdictions, with batch approval timelines extending up to 6 months in certain markets, impacting product availability and distribution efficiency.

Top 2 Companies by Market Share

• CSL holds approximately 20% global share with over 30 fractionation facilities worldwide.
• Takeda accounts for nearly 18% share, operating in more than 80 countries with plasma collection exceeding 8 million liters annually.

Investment Analysis and Opportunities

The Plasma Fractionation and Blood Product Market continues to attract large-scale capital allocation, with more than 30 fractionation capacity expansion projects initiated globally between 2023 and 2025. These projects collectively add close to 10 million liters of additional annual plasma processing capacity, increasing global fractionation throughput beyond 70 million liters per year. Approximately 40% of total new investments are directed toward immunoglobulin production lines, reflecting its 55% share of total plasma-derived product demand.

Around 25% of infrastructure expansion is concentrated in emerging markets across Asia-Pacific and Latin America, where domestic plasma sufficiency rates remain below 50% in several countries. Automation deployment has increased by 35% in newly commissioned plants, reducing manual processing steps by nearly 20% and improving batch yield efficiency by 5% to 8%. Over 50% of capital expenditure is allocated to cold chain systems operating between 2°C and 8°C, ensuring compliance with stringent transport standards across more than 80 importing nations. Additionally, roughly 30% of investment budgets are focused on pathogen safety enhancements and advanced chromatography purification systems, strengthening regulatory compliance across 25+ jurisdictions.

New Product Development

Product innovation within the Plasma Fractionation and Blood Product Market has intensified, with more than 15 new immunoglobulin formulations launched worldwide between 2023 and 2025. Immunoglobulin products account for approximately 55% of total plasma-derived therapeutic usage, and pipeline diversification reflects sustained clinical demand from over 6 million patients globally. Subcutaneous immunoglobulin (SCIG) delivery systems now represent a 20% increase in development pipelines, enabling home-based administration and reducing hospital infusion visits by nearly 30%.

Extended half-life coagulation factors comprise 25% of hematology-focused pipeline products, decreasing infusion frequency by approximately 35% compared to conventional regimens. Pathogen inactivation technology integration has risen by 30% across new product lines, incorporating solvent-detergent and nanofiltration processes that eliminate over 99% of enveloped viruses. Furthermore, more than 10 active clinical trials are evaluating hyperimmune globulins targeting emerging infectious diseases, expanding therapeutic application coverage by nearly 15%. Around 40% of investigational plasma-derived products focus on rare disease indications, reinforcing precision-based immunotherapy strategies within regulated treatment frameworks.

Five Recent Developments (2023–2025)

• In 2023, CSL expanded fractionation capacity by 1.5 million liters annually.
• Takeda opened 15 new plasma collection centers in 2024.
• Grifols increased immunoglobulin output by 12% in 2023.
• Octapharma launched 2 new SCIG formulations in 2024.
• Kedrion upgraded 3 fractionation facilities in 2025 to increase yield by 8%.

Report Coverage of Plasma Fractionation and Blood Product Market

The Plasma Fractionation and Blood Product Market Report delivers structured analysis across 4 major regions North America, Europe, Asia-Pacific, and Middle East & Africa—covering more than 20 countries with detailed quantitative benchmarks. The Plasma Fractionation and Blood Product Market Research Report evaluates over 30 leading manufacturers and regional players, assessing operational presence across more than 50 fractionation facilities and 1,000+ plasma collection centers. The study segments the Plasma Fractionation and Blood Product Market Size into 4 product categories immune globulin (approximately 55% share), albumin (20%), coagulation factors (8%), and other plasma derivatives (17%) alongside 3 application segments including immunology (60%), hematology (25%), and other therapeutic areas (15%).

The Plasma Fractionation and Blood Product Industry Report further examines supply chain metrics such as plasma collection volumes exceeding 60 million liters annually and manufacturing lead times averaging 7–9 months per batch. It incorporates regulatory assessments across 25 jurisdictions, where compliance requirements include more than 20 quality control tests per lot. Additionally, the Plasma Fractionation and Blood Product Market Insights analyze over 40 active clinical studies, including immunoglobulin expansion trials and extended half-life coagulation factor developments, offering actionable data for B2B stakeholders seeking Plasma Fractionation and Blood Product Market Opportunities and strategic capacity planning.